{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:45:05Z","timestamp":1784151905767,"version":"3.55.0"},"reference-count":53,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thrombocytopenia is one of the most common hematologic complications in cirrhosis. Despite limited data linking platelet count and bleeding risk in patients with cirrhosis, the use of platelets transfusions for invasive procedures has been a common practice. Recently, thrombopoietin (TPO) receptor agonists have been approved for use in patients with chronic liver disease (CLD) undergoing invasive procedures. The aim of this study was to review current literature on bleeding risk in patients with cirrhosis and the use of platelet transfusions and TPO receptor agonists in the context of invasive procedures. PubMed search was conducted to find articles relating to cirrhosis, thrombocytopenia, and new novel treatments for this condition. Search terms included CLD, cirrhosis, thrombocytopenia, bleeding, thrombosis, coagulopathy, hemostasis, and TPO receptor agonists. Romiplostim, eltrombopag, avatrombopag, and lusutrombopag are approved TPO receptor agonists, with avatrombopag and lusutrombopag specifically approved for use in patients with CLD undergoing invasive procedures. In patients with platelet counts\u2009&lt;\u200950,000\/mm3, avatrombopag and lusutrombopag increased the platelet counts above this threshold in the majority of treated patients and reduced the frequency of platelet transfusions. At the approved doses, incidence of thrombosis was not increased and therapies were well tolerated. Studies were not powered to assess whether risk of bleeding complications was reduced and the fundamental question of whether correction of thrombocytopenia is warranted in patients undergoing invasive procedures remains unanswered. The use of TPO receptor agonists has resulted in less requirement for platelet transfusions. In patients with cirrhosis undergoing invasive procedures for whom platelet transfusion is planned, TPO receptor agonists are an alternative and avoid the risks associated with transfusions. However, there is need for a thoughtful approach to manage bleeding risk in patients with cirrhosis undergoing procedures, with the consideration of a comprehensive hemostatic profile, the severity of portal hypertension, and the complexity of the invasive procedure to guide decisions regarding transfusions or use of TPO receptor agonists.<\/jats:p>","DOI":"10.1055\/s-0040-1715451","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:13:22Z","timestamp":1597968802000},"page":"682-692","source":"Crossref","is-referenced-by-count":27,"title":["Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease"],"prefix":"10.1055","volume":"46","author":[{"given":"Saro","family":"Khemichian","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases, Keck Medicine of University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases, Keck Medicine of University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/rth2.12028","article-title":"Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases","volume":"1","author":"T Lisman","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3350\/cmh.2016.0110","article-title":"Anticoagulation in cirrhosis: a new paradigm?","volume":"23","author":"F Leonardi","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"N M Intagliata","year":"2019","journal-title":"Gastroenterology"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA clinical practice update: coagulation in cirrhosis","volume":"157","author":"J G O'Leary","year":"2019","journal-title":"Gastroenterology"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"N Afdhal","year":"2008","journal-title":"J Hepatol"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1111\/j.1572-0241.2000.02325.x","article-title":"Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease","volume":"95","author":"F N Bashour","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ajh.2830500305","article-title":"Platelet autoantibodies in patients with chronic liver disease","volume":"50","author":"J Pereira","year":"1995","journal-title":"Am J Hematol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"T Lisman","year":"2006","journal-title":"Hepatology"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cgh.2010.03.025","article-title":"Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial","volume":"8","author":"L B Seeff","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/sjg.SJG_486_17","article-title":"Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis","volume":"24","author":"J Li","year":"2018","journal-title":"Saudi J Gastroenterol"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cgh.2010.06.018","article-title":"Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease","volume":"8","author":"E G Giannini","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.joms.2016.08.033","article-title":"Oral surgical treatment of patients with chronic liver disease: assessments of bleeding and its relationship with thrombocytopenia and blood coagulation parameters","volume":"75","author":"N Cocero","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.ijom.2018.04.007","article-title":"Bleeding during and after dental extractions in patients with liver cirrhosis","volume":"47","author":"J B Medina","year":"2018","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejim.2016.11.007","article-title":"Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia","volume":"38","author":"G Napolitano","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.27783","article-title":"Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study","volume":"62","author":"F Cerini","year":"2015","journal-title":"Hepatology"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"D C Rockey","year":"2009","journal-title":"Hepatology"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-016-9760-3","article-title":"Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update","volume":"11","author":"G Shiha","year":"2017","journal-title":"Hepatol Int"},{"issue":"03","key":"ref18","first-page":"155","article-title":"Current management of thrombocytopenia in chronic liver disease","volume":"15","author":"R S Brown Jr","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/lt.25198","article-title":"Management of coagulation and anticoagulation in liver transplantation candidates","volume":"24","author":"P Northup","year":"2018","journal-title":"Liver Transpl"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hep.28148","article-title":"Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial","volume":"63","author":"L De Pietri","year":"2016","journal-title":"Hepatology"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5604\/01.3001.0010.8635","article-title":"Viscoelastic testing in liver disease","volume":"17","author":"J PE Davis","year":"2018","journal-title":"Ann Hepatol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13054-016-1593-x","article-title":"Is platelet transfusion associated with hospital-acquired infections in critically ill patients?","volume":"21","author":"C Aubron","year":"2017","journal-title":"Crit Care"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/bjh.12017","article-title":"Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force","volume":"159","author":"H Tinegate","year":"2012","journal-title":"Br J Haematol"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1213\/ane.0b013e3181948a59","article-title":"Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury","volume":"108","author":"I T Pereboom","year":"2009","journal-title":"Anesth Analg"},{"issue":"S 01","key":"ref27","first-page":"41","article-title":"Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease","volume":"26","author":"R S Brown Jr","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/13696998.2019.1699563","article-title":"The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease","volume":"23","author":"M I Elsaid","year":"2020","journal-title":"J Med Econ"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.25842","article-title":"Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection","volume":"56","author":"S C Gordon","year":"2012","journal-title":"Hepatology"},{"key":"ref30","volume-title":"Nplate (Package Insert)","year":"2018"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ccr3.667","article-title":"Romiplostim therapy as a second-line treatment before splenectomy for refractory immune thrombocytopenia in a cirrhotic patient with iatrogenic Cushing syndrome secondary to corticosteroids","volume":"5","author":"T Casanovas Taltavull","year":"2017","journal-title":"Clin Case Rep"},{"issue":"01","key":"ref32","first-page":"97","article-title":"Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians?","volume":"37","author":"G Buccoliero","year":"2014","journal-title":"New Microbiol"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/MEG.0b013e328357d5f2","article-title":"Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports","volume":"24","author":"C S Voican","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4321\/S1130-01082011001000015","article-title":"Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure","volume":"103","author":"J Castellote","year":"2011","journal-title":"Rev Esp Enferm Dig"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1440-1746.2012.07246.x","article-title":"Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis","volume":"28","author":"M M Moussa","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"ref36","volume-title":"Promacta (Package Insert)","year":"2018"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","article-title":"Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy","volume":"146","author":"N H Afdhal","year":"2014","journal-title":"Gastroenterology"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"N H Afdhal","year":"2012","journal-title":"N Engl J Med"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.15574","article-title":"Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled phase 1 studies","volume":"183","author":"D J Kuter","year":"2018","journal-title":"Br J Haematol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"X19875105","DOI":"10.1177\/1179545X19875105","article-title":"Current advance in thrombopoietin receptor agonists in the management of thrombocytopenia associated with chronic liver disease: focus on avatrombopag","volume":"12","author":"J Abdela","year":"2019","journal-title":"Clin Med Insights Blood Disord"},{"key":"ref41","volume-title":"Doptelet (Package Insert)","year":"2018"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"N Terrault","year":"2018","journal-title":"Gastroenterology"},{"key":"ref43","volume-title":"Mulpleta (Package Insert)","year":"2018"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40265-015-0525-4","article-title":"Lusutrombopag: First Global Approval","volume":"76","author":"E S Kim","year":"2016","journal-title":"Drugs"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","article-title":"Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures","volume":"17","author":"H Hidaka","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2)","volume":"70","author":"M Peck-Radosavljevic","year":"2019","journal-title":"Hepatology"},{"issue":"S 01","key":"ref47","first-page":"1093A","article-title":"Lusutrombopag for the Managment of Thrombocytopenia in Chronic Liver Disease Patients with Comorbid Obesity or Diabetes","volume":"70","author":"T Hassanein","year":"2019","journal-title":"Hepatology"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"e0211122","DOI":"10.1371\/journal.pone.0211122","article-title":"Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures","volume":"14","author":"H Takada","year":"2019","journal-title":"PLoS One"},{"issue":"S 01","key":"ref49","first-page":"265A","article-title":"Effectiveness and Safety of Thrombopoietin-Receptor Agonist Lusutrombopag for Chronic Liver Disease Patients Who Undergo Elective Invasive Procedures: Results from a Real-World, Multicenter Study","volume":"70","author":"N Taniki","year":"2019","journal-title":"Hepatology"},{"issue":"46","key":"ref50","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.3748\/wjg.v24.i46.5271","article-title":"Relationship between response to lusutrombopag and splenic volume","volume":"24","author":"H Uojima","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dld.2018.06.005","article-title":"Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: a meta-analysis","volume":"51","author":"L Loffredo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"ref52","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"W Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"21","key":"ref54","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2169\/internalmedicine.8791-16","article-title":"Efficacy of repeated lusutrombopag administration for thrombocytopenia in a patient scheduled for invasive hepatocellular carcinoma treatment","volume":"56","author":"S Sato","year":"2017","journal-title":"Intern Med"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"W Ghanima","year":"2019","journal-title":"Haematologica"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1715451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T22:36:56Z","timestamp":1599691016000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1715451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":53,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2020,9,9]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1715451","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}